Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional) | PA 21 232

Opportunity Information: Apply for PA 21 232

The NIH funding opportunity PA-21-232, titled "Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)," supports research projects that improve how type 2 diabetes is managed in groups that experience persistent health and health care disparities. The central focus is on developing and/or testing innovative interventions that are multidisciplinary (drawing from multiple fields such as medicine, nursing, pharmacy, public health, behavioral science, informatics, and community partners) and multi-level (addressing factors at the patient, family, clinician, clinic/health system, and community levels). While many diabetes initiatives concentrate mainly on blood sugar control, this FOA emphasizes comprehensive, guideline-concordant care, meaning projects should help patients not only reach glycemic targets but also receive the full set of recommended preventive and risk-reduction services that are often missed in real-world care.

The FOA is specifically aimed at NIH-designated health disparity populations. These include racial and ethnic minority groups (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minority populations, socioeconomically disadvantaged populations, and underserved rural populations. Applications are expected to be patient-centered and designed around the lived realities of these communities, including barriers like limited access to specialty care, transportation challenges, underinsurance, cost-related medication nonadherence, language barriers, discrimination, fragmented care, and lower availability of culturally responsive services. The overall intent is to close gaps in quality of care and outcomes by ensuring evidence-based diabetes care actually reaches people who have historically been left behind.

Projects funded under this announcement are expected to go beyond improving A1c and to address other core elements of diabetes care that prevent complications and reduce cardiovascular and kidney risks. The FOA explicitly highlights targets such as completion of annual eye exams and foot exams, screening for kidney disease (for example, urine albumin testing), optimizing blood pressure control, and improving appropriate use of protective medications when indicated, including ACE inhibitors or ARBs, statins, and aspirin. It also calls attention to vaccination uptake, such as influenza and pneumonia vaccines, which are important preventive measures for many adults with diabetes but are unevenly implemented. In practice, strong applications would typically propose strategies that improve reliable delivery and follow-through on these multiple guideline components, rather than addressing them in isolation.

The mechanism is an R01 research project grant, and clinical trials are optional, meaning applicants may propose either observational/intervention development work or a full trial depending on the research question and readiness of the intervention. The work should be innovative and rigorous, often involving implementation strategies, care delivery redesign, team-based models, health IT or decision support, community-clinical linkages, culturally tailored education or navigation, medication access supports, or approaches that reduce structural barriers to care. Because the FOA emphasizes multi-level interventions, competitive projects commonly incorporate both patient-facing components (education, coaching, self-management support, navigation) and system-facing components (workflow changes, clinician decision support, performance feedback, referral tracking, and partnerships with community organizations).

Eligibility is broad and includes many U.S.-based organizations across sectors. Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; small businesses; and other organizations. The announcement also explicitly notes additional eligible applicant types commonly involved in disparity-focused work, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), faith-based or community-based organizations, regional organizations, and U.S. territories or possessions. At the same time, it clearly excludes foreign institutions and foreign components: non-U.S. entities cannot apply, non-U.S. components of U.S. organizations are not allowed, and foreign components as defined by NIH policy are not permitted.

From an administrative standpoint, this is a discretionary grant administered by the National Institutes of Health, listed under CFDA numbers 93.307, 93.313, 93.847, and 93.867, and categorized under health-related funding activity areas (including food and nutrition and health). The opportunity lists an award ceiling of $500,000, which typically signals the expected maximum annual direct cost level or a similar budget constraint depending on NIH policy and the specific institute/center guidance for the FOA. The original closing date provided is 2024-09-07. Overall, the FOA is designed to generate practical, evidence-based approaches that measurably improve comprehensive diabetes care delivery for adults in disparity populations, with the larger goal of reducing preventable complications and narrowing inequities in outcomes.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.307, 93.313, 93.847, 93.867.
• This funding opportunity was created on 2021-05-26.
• Applicants must submit their applications by 2024-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PA 21 232

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: